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1United States Army; 2Simpson College 
 
Abstract 
Objectives: The primary objective is to investigate the public’s perception about the role of the community pharmacist in Peru’s directly 
observed treatment, short course (DOTS) program. The secondary objective is to assess perceived barriers that would prevent the public 
from utilizing community pharmacists in order to identify future opportunities for community pharmacists to increase adherence to 
multidrug-resistant tuberculosis (MDR-TB) therapy. Design: Qualitative study comprised of an 8 close-ended survey questionnaire. 
Setting: Healthcare clinics established by a medical mission group in Lima and surrounding communities, Peru, from July 13 to July 27, 
2015. Participants: Patients 15 years of age and over who sought healthcare at the clinics. Main outcome measures: Public’s 
perception about the role of the community pharmacist in Peru and barriers that would prevent the public from seeking a community 
pharmacist. Results: Out of the 445 patients approached, 438 patients completed the survey, resulting in a 98% response rate. More 
than half (52%) of the respondents were likely to seek a community pharmacist to assist them in completing a MDR-TB medication 
regimen. Almost half (48%) of the respondents felt comfortable with assistance of a community pharmacist in completing an MDR-TB 
regimen. The physician was the first health care professional that was contacted for all medical situations, including drug-related 
questions (61%). Lack of privacy in the pharmacy (53%) and busyness of the pharmacists (52%) were the top perceived barriers for 
asking community pharmacists questions. Conclusion: This study highlights the need for pharmacist participation in Peru’s DOTS 
program. Furthermore, this investigation has identified several issues of concern related to current community pharmacy practice in 
Peru. Therefore, future efforts may be necessary to address these identified areas of opportunity to promote the community 
pharmacist’s role in health screening, drug therapy monitoring, and counseling to decrease the public health burden of MDR-TB. 
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Introduction 
Tuberculosis (TB) is one of the oldest diseases known to man, 
caused by the bacteria Mycobacterium tuberculosis that 
affects the lungs and other parts of the body, such as the spine, 
kidneys and brain.  In most cases, TB is treatable and curable, 
given proper and timely treatment.  However, if left untreated 
or improperly treated, TB causes progressive tissue 
destruction and, eventually, death.1  The first drug to be used 
for TB was streptomycin, initially providing successful clinical 
improvement.  However, drug-resistance was recognized 
shortly after its introduction in the 1940s, demonstrated by 
treatment failure following the first three months of therapy 
in 82 percent of patients being treated with streptomycin.2  
The term drug-resistant TB refers to cases of TB caused by an 
isolate of M. tuberculosis that is resistant to one of the first-
line treatment options, including ethambutol, isoniazid, 
pyrazinamide, rifampin or streptomycin.3  Multidrug-resistant 
tuberculosis (MDR-TB) refers to an isolate of M. tuberculosis 
that is resistant to at least isoniazid and rifampin, the two most 
effective first-line medications.1,2,3  Extensively drug-resistant 
tuberculosis (XDR-TB) is a type of MDR-TB that is resistant to 
isoniazid and rifampin, plus any fluoroquinolone and at least 
one of three injectable second-line medications (amikacin, 
kanamycin, or capreomycin).4 
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TB remains a concerning global infectious disease, and a 
leading cause of morbidity and mortality in the world.5  In fact, 
TB is second only to HIV/AIDS as the greatest global killer due 
to a single infectious agent.6  The World Health Organization 
(WHO) reported 9 million cases of TB and 2 million deaths in 
2013.  Of these cases, approximately 480,000 developed MDR-
TB and 210,000 deaths occurred.  Globally, MDR-TB incidence 
has decreased between 1993 and 2013 from 2.4 percent to 1.3 
percent.  Despite the overall decline, surveys of worldwide 
drug resistance indicate MDR-TB is a major and increasing 
crisis, with increasing rates in the country of Peru.2  It is 
necessary to emphasize that MDR-TB is a man-made public 
health issue.7,8  As previously mentioned, TB is treatable and 
curable.  Inadequate health systems, however, contributes to 
delayed diagnosis and insufficient and incomplete treatment.9  
The development of MDR-TB is precipitated by an inadequate 
course of treatment.  The reason for this is multifactorial, 
including improper health care provider prescribing practices, 
poorly supervised treatment programs, inadequate infectious 
disease control in hospitals and prisons, patient medication 
noncompliance, and limited access to health care.10 
 
The epidemiology of MDR-TB is complex, needing control 
efforts targeting the multi-level factors.  There are several 
public health interventions necessary for the reduction of 
MDR-TB including diagnosis, treatment, and medication 
adherence promotion.  Directly observed treatment, short-
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course (DOTS) refers to a TB control strategy outlined by the 
WHO, with the following components:  increased financing, 
case detection, supervised standardized treatment and 
monitoring, effective drug supply and management.  The 
program requires a laboratory confirmed TB diagnosis by a 
trained clinician, procurement of TB drugs, and medication 
adherence enforcement through direct observation by a 
health care provider.11 
 
The disease imposes an economic and social burden on 
societies. It is estimated that about 2 billion dollars per year is 
required for the proper detection and treatment of MDR-TB; 
an additional 2 billion dollars is required for research and 
development for novel vaccinations, drugs and diagnostics for 
TB.12,13  Managing MDR-TB cases is extremely challenging.  
Current treatment regimens of MDR-TB use drugs that are less 
effective, more toxic and often must be administered for 12 to 
18 months.1  Directly observed therapy (DOT) refers to a 
strategy in which a patient takes each prescribed dose of a 
medication in front of a health care provider.  MDR-TB 
programs that include DOT have reduced the transmission of 
the disease in communities in Baltimore and New York.14  
 
In 1990, Peru’s National Tuberculosis Control Program (NTP) 
made revisions to follow the WHO’s DOTS approach, including 
case detection, diagnosis, and directly observed therapy.  The 
composition of the teams included a doctor, a nurse, a social 
worker, a trainer, a nutritionist, a lab technician, a nurse 
technician, and a logistics coordinator.  Nurses administered 
the drugs in a health care facility, incentivizing the patients 
with food packages, employment training, and free 
transportation.15  Despite these achievements, Peru continues 
with a high prevalence of MDR-TB and XDR-TB, concentrating 
in Lima and El Callao.  Over the 2006-2013 period, morbidity 
from TB was 108.5 per 100,000.  In 2013, there were 27,504 
new TB cases reported and 1,462 laboratory-confirmed MDR-
TB cases, with 80% of cases diagnosed in the age group from 
15 to 59 years old.  Furthermore, 59% of the drug-sensitive TB 
cases, 82% of the MDR-TB cases, and 93% of the XDR-TB cases 
occurred in Lima and El Callao.16,17  
 
The current DOTS program exists in an effort to control 
morbidity and mortality of tuberculosis, with no participation 
of community pharmacists.  The rising rates of MDR-TB in Peru 
demonstrate its shortfalls.  Therefore, methods of DOTS in the 
country need to be improved so that every at-risk individual is 
reached.  In addition, DOTS programs should also be scaled up 
to ensure that every at-risk MDR-TB patient in the community 
is targeted.  This is not currently common practice, nor the 
intention of DOTS programs around the world, but a campaign 
for eradication—not just control—should entail all members 
of the population afflicted by TB.14  
 
As previously mentioned, the most important preventative 
measure against MDR-TB is adherence and completion of the 
prescribed TB medication regimen, and proper medication 
counseling by health care professionals including expected 
side effects, duration of treatment, and pertinent information 
increases medication compliance in MDR-TB patients.18  Failure 
of patients to follow medication directions has been well 
established regardless of age or social standing.19  The reasons 
for non-compliance are multifactorial, including adverse 
effects, drug-drug interactions, and misunderstanding of 
directions by patients.20  Medication compliance is the extent 
to which the patient takes medications as directed.  Failure of 
medication compliance, or non-compliance, has been well 
established regardless of age or social standing.21,22  Factors 
that cause MDR-TB non-adherence and incompletion of the 
prescribed medication regimen include length of treatment 
and drug-related problems, including adverse effects and 
interactions, contribute to patient non-compliance.18,23  As 
previously mentioned, treatment regimens for MDR-TB must 
be administered for 12 to 18 months.  Podewils, Gler, 
Quelapio, and Chen24 found that patients were 3 to 4 times 
more prone to interrupt their MDR-TB treatment between 6 
and 12 months and 12 to 18 months after initiating treatment.  
Hirpa et al.11 concluded that proper medication counseling by 
health care professionals, including expected side effects, 
duration of treatment, and pertinent information increases 
medication compliance, the most important preventative 
measure against MDR-TB, in these patients.  Pharmacists, drug 
experts, are in a unique position to provide this crucial 
counseling of MDR-TB medications to ensure adherence and 
completion of the regimen.25  However, if pharmacists are not 
perceived as essential or indispensable, and patients do not 
seek a community pharmacist for medication advice to 
improve compliance, their role seems to be uncertain. 
 
Pharmacy Practice in Peru 
Approximately 10,000 pharmacies serve the population of 
Peru, and must be registered with the Ministry of Health.  
There are currently 17 schools of pharmacy in the country.  The 
curriculum is five years followed by six to twelve months of 
practice.  The duration of this internship is different for each 
university because there is no formal accreditation process.  
After graduation, pharmacists can attend continuing 
education programs that are provided by the National 
Pharmacy Board and universities.26 
 
The Ministry of Health issues the norms for dispensing drugs in 
pharmacies in Peru.  The Good Practice of Dispensing Manual 
outlines, regulates, and establishes the dispensing process.  
The norms require a safe distribution and dispensing process 
to reduce negative clinical outcomes.  The law mandates that 
a pharmacist must be on the premises to dispense 
medications.  However, this function is often performed by 
pharmacy technicians or assistants.  In Peru, it is uncommon 
for information, including a medication monograph with 
expected side effects, instructions on missed doses, and other 
pertinent details, to be provided when a patient is dispensed a 
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drug.  Although patients seek the advice of pharmacists 
regarding their disease states and medication use, there are no 
protocols for this activity.  Medication counseling by a 
pharmacist is rarely performed to patients because the offer 
to counsel is not mandated by law.  Thus, a patient may not be 
aware of such a service, and may lead to medication non-
compliance.16  If a patient does request counseling, 
pharmacists are required by the law to inform patients about 
the reason(s) for use of the medications and what effect to 
expect, the correct use of the medication, necessary actions 
for missed doses, and the use of devices such as asthma 
inhalers or insulin injections.26   
 
Objectives 
To our knowledge, no other research has been published 
assessing the public’s attitudes toward the community 
pharmacist’s role in Peru.  The present study aimed to 
investigate the public’s perception about the potential role of 
the community pharmacist in Peru’s DOTS program.  
Furthermore, it served to assess perceived barriers that would 
prevent the public from utilizing community pharmacists in 
order to identify future opportunities for community 
pharmacists to increase adherence to MDR-TB therapy. 
 
Methods 
Participants 
The survey canvassed 445 patients in 5 different communities 
outside of Lima, where clinics were established to serve the 
medical needs of several communities.  The participants 
included in this project were the patients that the primary 
researcher, a registered pharmacist, served during the clinic 
days.  A non-probability, convenience sampling technique was 
used.  This investigation attempted to provide insight 
regarding the patients’ perception of community pharmacists 
to find ways to reduce the incidence of MDR-TB; patients that 
are representative of the entire population will not be 
considered.  Therefore, participants were selected because of 
their convenient accessibility and proximity to the 
researcher.27  Des Moines University Institutional Review 
Board approved all survey procedures prior to survey 
commencement.   
 
Instruments 
The in-person surveys utilizing a questionnaire (Appendix 1) 
were developed to assess the patients’ perception of 
community pharmacists and barriers that would prevent the 
patients from seeking medical expert advice from a 
pharmacist. Six pharmacists were invited to assess the content 
validity of the questionnaire.  In addition, the survey was 
translated into Spanish, and pretested in Peru by a translator 
to examine participants’ responses to the survey and to 
evaluate the reliability of the data yielded by the 
questionnaire.   
 
The current survey consisted of eight close-ended, 
comprehensible, and easy to understand questions.  The close-
ended questions provide easier categorizations and 
quantification of findings, and minimize inadvertent bias in 
interpreting specific responses.  These questions were 
adaptations from the questionnaires used in the study 
performed by Al-Arifi,28 and El Hajj, Salem, and Mansoor,29 that 
surveyed patients to gain insight about the population 
perception regarding pharmacist’s performance as health care 
providers in the community setting.  A 5-point Likert scale (not 
at all, slightly, somewhat, very, extremely) was utilized for four 
questions to measure the extent to which patients agree with 
statements regarding accessibility of healthcare clinics and 
pharmacists, and the likelihood and comfort level of the 
patients to seek the advice and expertise of a community 
pharmacist for MDR-TB (Table 2).  One question assessed 
barriers that would prevent the participants from asking any 
questions to a community pharmacist by selecting all 
applicable statements from a list.  Three questions included 
close-ended questions asking respondents about what 
healthcare professional they would choose for certain medical 
situations and conditions.  
 
Data collection and analysis 
Portable clinics were implemented by a medical mission group, 
and provided primary care, optometry, dental, and pharmacy 
services.  The pharmacy in the clinics mirrored the design of a 
community pharmacy, in that medications were dispensed 
from a prescription written by a health care provider.  
Functionally, the portable clinics mimicked community 
pharmacies, therefore, it is reasonable to assume patients’ 
expectations for the role of community pharmacies and 
pharmacists, as well as the services received between the two 
types of sites, would be similar.  After providing medications 
to the patients, the translator and researcher asked every fifth 
patient that sought pharmacy services from the established 
clinics to participate in the study.  The in-person surveys 
utilizing a questionnaire were anonymous.   Responses were 
coded and reviewed for accuracy.  Descriptive statistics, 
including percentages and frequencies, were computed to 
summarize survey findings, with all computations performed 
using SPSS version 22.0. 
 
Results 
Survey sample 
During the two week study period, 445 patients were 
approached, and 438 (Table 1) of them answered the survey, 
resulting in a 98% response rate.  Respondents varied in age 
from 15-88 years, with a mean age of 43 years.  Approximately 
half of the respondents were from age groups of 36-45 (24.7%) 
and 56 and above (24.7%).  Male respondents are 52%, while 
female respondents are 48%.  Additionally, married 
respondents are greater in number (58.4%), compared to 
single and others. 
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Patients’ perception on accessibility of healthcare and 
community pharmacists, and involvement of community 
pharmacists in MDR-TB therapy  
Table 2 summarizes the patients’ perception of burden in 
accessing healthcare and community pharmacists and the 
patients’ perception of the community pharmacist’s 
involvement in MDR-TB therapy.  These results showed 6.4% 
of participants were not at all burdened, 34.7% slightly 
burdened in accessing a healthcare clinic with a doctor or 
nurse, 33.8% were slightly burdened, 17.6% were very 
burdened, and 7.5% were extremely burdened.  Furthermore, 
the results showed 22.6% were not at all burdened, 26% were 
slightly burdened in accessing a community pharmacist, 24% 
were slightly burdened, 21.9% were very burned, and 5.5% 
were extremely burdened.  
 
Additionally, when asked if the respondents already had 
tuberculosis, 34% were very likely and 17.8% were extremely 
likely to seek a pharmacist to help them complete their 
medication regimen.  Only 21.9% were somewhat likely, 24% 
were slightly likely, and 2.3% were not at all likely to seek a 
pharmacist to assist them complete their TB medication 
therapy.  Furthermore, 30.8% of the respondents were very 
comfortable and 17.4% were extremely comfortable with the 
pharmacist’s involvement of ensuring the completion of an 
MDR-TB medication therapy, while 24.4% were slightly 
comfortable, 22.1% were slightly comfortable, and 5.3% were 
not at all comfortable.  
 
Patients’ choice of a healthcare professional for obtaining 
medications 
As shown in Table 3, more than half of the survey respondents 
(58.4%) seek a doctor to provide them with their medications, 
while only 18.7% seek a community health worker, 13.7% seek 
a pharmacist, and 9.1% seek a nurse.  Furthermore, a majority 
of survey respondents (82.2%) of survey respondents would 
seek a doctor for tuberculosis medications if diagnosed with 
the disease state, while only 7.1% would seek a community 
health worker, 6.4% would seek a nurse, and 4.3% would seek 
a pharmacist.    
 
Potential barriers of asking questions to a community 
pharmacist 
As shown in Table 4, survey respondents most frequently cited 
busyness of pharmacists (52.1%) and lack of privacy in the 
pharmacy (53%), and a higher trust in doctors compared with 
pharmacists (45.7%).  Other barriers included lack of 
awareness of the ability of the pharmacist to answer drug and 
disease related questions (38.4%), fear or intimidation of 
asking the pharmacist (30.1%), unavailability of the 
pharmacists to answer my questions (30.1%), and lack of the 
pharmacist’s knowledge to answer drug and disease related 
questions (25.6%).  It is important to note that multiple 
responses were permitted for this question; therefore, the 
percentages cannot be added together.  The results basically 
represent rankings of the potential barriers. 
 
Patients’ choice of a healthcare professional for various health 
reasons 
As shown in Table 5, for all five situations, survey respondents 
chose doctors as the first healthcare professional they would 
visit for mental and emotional problems (67.1%), questions 
regarding medication side effects (54.6%), how to properly 
take medications (51.8%), drug-related questions (61.2%), and 
selecting over-the-counter medication products (41.8%).   
 
Discussion 
This study was the first of its kind in Peru to examine the 
general public’s perception regarding community pharmacy 
services in an attempt to identify areas of opportunity for 
pharmacists to increase adherence to prescribed MDR-TB 
treatment.  Several issues of concern, however, related to 
current community pharmacy practice in Peru were raised in 
this study.  An overwhelming 82.2% of participants would seek 
a doctor first for medications for MDR-TB, and 55% rated the 
physician as their primary source of medication-related 
information.  Furthermore, when asked about different 
barriers preventing them from asking the community 
pharmacist drug-related questions, 45.7% of patients felt 
higher trust in doctors compared to pharmacists.  This agrees 
with a study by El Hajj et al.,29 who found physicians were 
considered the first healthcare professional contacted by 
patients to answer drug-related questions by 50% of 
respondents.  Unfortunately, this suggests a problem with the 
patient-pharmacist relationship in Peru, reinforcing the 
importance of comprehensive and regular medication 
counseling by pharmacists; obligations rarely offered in 
community pharmacies in Peru.  The respondents who did not 
consider the community pharmacist as their primary source of 
medication-related questions may not be aware that the 
pharmacists are trained and capable of providing such 
services.  Therefore, Peru’s community pharmacists should 
participate in MDR-TB public health campaigns to raise 
expectations from the public and other healthcare 
professionals about their professional role.  This campaign 
must demonstrate the potential benefits of MDR-TB 
medication adherence and completion with pharmacists’ 
involvement by extending their contributions to medication 
use beyond ensuring accurate dispensing.   
 
The results of this investigation showed the patients’ 
perceived accessibility to community pharmacists and 
healthcare clinics with a provider or nurse to be about equal.  
Approximately 73% of respondents were not burdened or 
somewhat burdened in seeking a pharmacist.  Therefore, 
community pharmacists in the country are ideally positioned 
to serve as a public health resource to diagnose and treat 
ailments, including MDR-TB.  However, from the patients’ 
perspective of this study, it does not appear that community 
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pharmacists are taking full advantage of this benefit of 
accessibility.  Although 10,000 pharmacies serve the 
population of Peru, 52.1% and 30.1% of respondents in this 
study perceived busyness of the pharmacists and unavailability 
of the pharmacists to answer drug-related questions, 
respectively, as barriers of communicating with community 
pharmacists.  This agrees with the results of Al Akshar, 
Metwaly, and Shamssain,30 which showed 35% and 36% of 
respondents perceived the same barriers, respectively.  These 
perceived barriers appear to support the findings that in Peru 
few pharmacists are on location, and the dispensing is often 
performed by assistants who are not always technicians, even 
though the law requires a pharmacist on the premises during 
business hours.  Additionally, patients are not regularly offered 
medication counseling by a pharmacist because the law does 
not require it.  Therefore, in order for Peru’s pharmacists to 
allocate adequate and quality time with their patients, more 
pharmacy technicians need to be hired; delineating the roles 
between pharmacists and technicians.  Thus, pharmacists can 
devote more time to patient-centered activities, including 
MDR-TB medication counseling, while technicians focus on the 
dispensing processes.   Furthermore, medication counseling by 
a pharmacist must be legally offered to every patient that 
obtains medications.   
 
Privacy in the pharmacy was another issue raised in this study.  
Of particular note, 53.0% of respondents stated that a lack of 
privacy in the pharmacy was a barrier to seek the help of a 
community pharmacist.  This can be attributed by the lack of 
private consultation areas in the majority of community 
pharmacies in Peru, as shown in a study by Alvarez-Riscol, et 
al.26  Additionally, 30.1% of the respondents were fearful or 
intimidated of asking a pharmacist medication related 
questions.  Perhaps, if community pharmacies invested in 
consultation rooms or areas, more patients would seek 
pharmaceutical care counseling without the perceived fear or 
intimidation.    
 
The last issue of concern was the patients’ lack of awareness 
of the ability of the pharmacist to answer drug and disease 
related questions.  Approximately 40% of the participants 
viewed this issue as a barrier of seeking the help of community 
pharmacists.  The study by Alvarez-Risco, et al.,26 evaluating 
the pharmaceutical care in Peruvian community pharmacies, 
provides insight on this issue.  First, Peru’s community 
pharmacists are trained from diverse curricula; some not 
adequately preparing graduates to assume the role of 
pharmaceutical care providers.   Second, pharmacy continuing 
education is rarely offered to Peru’s community pharmacists, 
and is not required for licensure.  Future recommendations to 
address these deficiencies include development of uniform 
concepts in research and training, development of protocols 
for pharmaceutical care activities, laws mandating a minimum 
number of continuing education credits for licensure renewal 
to ensure participation in inter-professional pharmacy 
programs.   
 
The results of the survey are promising in terms of advancing 
the community pharmacist’s role in Peru.  More than half 
(51.8%) of the patients would be extremely/very likely to visit 
a pharmacist for assistance in completing an MDR-TB 
medication regimen.  Furthermore, almost half (48.2%) would 
be extremely/very comfortable with a pharmacist’s 
involvement in completion of an MDR-TB medication 
treatment.  These findings support the claim that patients seek 
the advice of pharmacists regarding their disease states, 
including MDR-TB, and medication use.  Although patients may 
not consider the pharmacist as their first choice to answer 
their medication-related questions, they view pharmacists as 
capable of integrating disease state management with 
medication compliance.  This shows the public’s awareness of 
the various professional services that community pharmacists 
can provide; beyond the duty of accurately dispensing 
medications.  These findings contradict the results of other 
studies, including Iverson et al.,31 where participants did not 
expect the community pharmacist to monitor their long-term 
illnesses.  Additionally, El Hajj et al.29 claimed that more than 
70% of participants disagreed with the expectation of a 
pharmacist to assess the patient’s health progress to ensure 
safe and effective medication use.  As previously mentioned, 
these tasks are the precise elements necessary to increase the 
adherence and ensure completion of an MDR-TB medication 
regimen.  Promisingly, the results of this study show that if 
community pharmacists in Peru were to expand their role to 
cognitive pharmaceutical care, the patient would be likely and 
comfortable to seek pharmacist-involved MDR-TB services.  
Therefore, from the patients’ perspective, pharmacists could 
assume the role of administering MDR-TB medications in 
Peru’s DOTS program to ensure adherence and completion 
with proper medication counseling, including expected side 
effects, duration of treatment, and pertinent information.   
 
Limitations 
This study had several limitations.  First, a convenience sample 
was used, and may not fully represent the whole population in 
Peru.  Second, the surveys were conducted after participants 
sought pharmaceutical care at the clinics established by the 
medical mission team.  This could lead to potential bias in 
responses, as patients may have felt obligated to respond 
positively after receiving such care.  Third, the survey was 
conducted in a direct questioning manner, potentially causing 
the patients to feel rushed in answering the questions.  Finally, 
the study relied on translation and interpretation.  As it was 
culturally appropriate to do so, it is possible that there was an 
imperfect translation, even though careful planning, piloting, 
and consideration were given prior to beginning the study. 
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Conclusion 
This study is the first known attempt to investigate the public’s 
perception about the role of the community pharmacist in 
Peru in order to identify future opportunities for pharmacists 
to increase adherence to MDR-TB therapy.  Despite its 
limitations, this study provided valuable data, on which future 
investigations can be built.  The study suggested a strong 
likelihood and comfort of the public in seeking the community 
pharmacist if they were diagnosed with MDR-TB.  Therefore, 
from the patients’ perspective of this study, participation of 
the pharmacist in the Peru’s DOTS program could potentially 
increase patients’ adherence to an MDR-TB medication 
regimen, thus decreasing this public health burden in a country 
with rising rates of this disease state.   
 
Patient adherence and completion of a prescribed TB 
medication regimen is the most important preventative 
measure against MDR-TB.  It is clear that comprehensive 
medication counseling to include expected side effects, 
duration of treatment, and pertinent information increases 
medication compliance.  Community pharmacists in Peru are 
in a unique position to provide this vital information to MDR-
TB patients.  Additionally, the results of this investigation 
reveal that pharmacists are perceived as important members 
of the healthcare team, as demonstrated by their awareness 
of their various roles and services.  Therefore, community 
pharmacists should provide comprehensive counseling to all 
patients with MDR-TB.  
 
The investigation revealed several perceived barriers that 
would prevent the public from utilizing community 
pharmacists, including lack of privacy in the pharmacy, 
unawareness of pharmacist abilities to answer drug and 
disease related questions, and inadequate pharmacist-patient 
contact time.  Future studies focusing on the pharmacists’ 
perception regarding these barriers would be necessary and 
revealing.  These investigations would likely provide insight on 
the challenges of the community pharmacist, including daily 
operations in the pharmacy that prevent comprehensive 
medication counseling.   
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Appendix 1 
Participants’ Demographics: 
Age Gender Marital Status 
  
M            F 
 
Single          Married           Divorced         Widow  
 
Question 1: 
Rate your burden on getting to a healthcare clinic with a doctor or nurse from 1 (not at all burdensome ) to 5 
(extremely burdensome): 
1 
Not at all 
Burdensome 
2 
Slightly 
Burdensome 
3 
Somewhat 
Burdensome 
4  
Very 
Burdensome 
5 
Extremely 
Burdensome 
 
Question 2: 
Rate your burden on getting to a community pharmacist from 1 (not at all burdensome ) to 5 (extremely 
burdensome): 
1 
Not at all 
Burdensome 
2 
Slightly 
Burdensome 
3 
Somewhat 
Burdensome 
4  
Very 
Burdensome 
5 
Extremely 
Burdensome 
 
Question 3: 
What healthcare professional do you seek to provide you with medications?  (Choose one) 
 
Doctor 
 
Nurse          
 
Pharmacist           
      
Community health workers 
 
Question 4: 
If you already had tuberculosis, who would you go see first for your medications?  (Choose one) 
 
Doctor 
 
Nurse          
 
Pharmacist           
      
Community health workers 
 
Question 5: 
If you already had tuberculosis, how likely would you seek a community pharmacist to help you take all of your 
medications from 1 (not at all likely) to 5 (extremely likely)? 
1 
Not at all 
Likely 
2 
Slighlty 
Likely 
3 
Somewhat 
Likely 
4  
Very  
Likely 
5 
Extremely 
Likely 
 
Question 6: 
If you already had tuberculosis, rate your comfort level of a community pharmacist to help you take all of your 
medications from 1 (not at all comfortable) to 5 (extremely comfortable)? 
1 
Not at all 
Comfortable 
2 
Slightly 
Comfortable 
3 
Somewhat 
Comfortable 
4  
Very 
Comfortable 
5 
Extremely 
Comfortable 
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Question 7: 
What barriers prevent you from asking any question to a community pharmacist?  (Choose all that apply) 
 
 ☐ Fear or intimidation of asking the pharmacist 
 ☐ Lack of awareness of the ability of the pharmacist to answer drug and disease related questions 
☐ Lack of pharmacist’s knowledge to answer drug and disease related questions 
 
 ☐ Busyness of the pharmacists 
 ☐ Lack of privacy in the pharmacy 
 ☐ Unavailability of the pharmacists to answer my questions 
 ☐ Doctors are trusted more than pharmacists 
 ☐ Doctor will be offended if I ask the pharmacist 
 
Question 8: 
For each of the following, who would you go to first? 
 
a.  Talk to me when I am fearful, distressed, concerned, or sad mentally or emotionally 
 
Doctor   
 
Pharmacist 
 
Nurse 
 
 
b.  Talk to me about serious side effects of my medications 
 
Doctor   
 
Pharmacist 
 
Nurse 
 
 
c.  Talk to me about how to take medications 
 
Doctor   
 
Pharmacist 
 
Nurse 
 
 
d.  Talk to me about my drug related questions 
 
Doctor   
 
Pharmacist 
 
Nurse 
 
 
e. Talk to me about products I can get over-the counter, such as cough and cold medicine 
 
Doctor   
 
Pharmacist 
 
Nurse 
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Table 1.  Demographics of survey respondents (n=438) 
Characteristics No. (%)  
(unless otherwise indicated) 
Age  
     Mean (range) 43 (15-88) 
     15-25 67 (15.3) 
     26-35 95 (21.7) 
     36-45 108 (24.7) 
     46-55 60 (13.6) 
     56 and above 108 (24.7) 
 Sex  
     Male 228 (52) 
     Female 210 (48) 
Marital status  
     Single 172 (39.3) 
     Married 256 (58.4) 
     Divorced 3 (0.69) 
     Widowed 7 (1.6) 
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Table 2. Survey respondent perceptions of accessibility of healthcare  and community pharmacists, and 
involvement of community pharmacists in MDR-TB therapy (n=438) 
Item No. (%) 
Rate your burden on getting to a healthcare clinic with a doctor or nurse.  
     Not at all burdensome 28 (6) 
     Slightly burdensome 152 (35) 
     Somewhat burdensome 148 (34) 
     Very burdensome 77 (18) 
     Extremely burdensome 33 (7) 
Rate your burden on getting to a community pharmacist.  
     Not at all burdensome 99 (23) 
     Slightly burdensome 114 (26) 
     Somewhat burdensome 105 (24) 
     Very burdensome 96 (22) 
     Extremely burdensome 24 (5) 
If you already had tuberculosis, how likely are you to seek a community pharmacist to help 
you take all of your medications? 
 
     Not at all likely 10 (2) 
     Slightly likely 105 (24)  
     Somewhat likely 96 (22) 
     Very likely 149 (34) 
     Extremely likely 78 (18) 
If you already had tuberculosis, rate your comfort level of a community pharmacist to help 
you take all of your medications. 
 
     Not at all comfortable 23 (5) 
     Slightly comfortable 97 (22) 
     Somewhat comfortable 107 (25) 
     Very comfortable 135 (31) 
     Extremely comfortable 76 (17) 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                           2017, Vol. 8, No. 3, Article 11                      INNOVATIONS in pharmacy   12 
 
 
  
Table 3.  Survey respondent opinions about choice of healthcare professional for obtaining medications (n=438) 
Item No. (%) 
What healthcare professional do you seek to provide you with medications?  
     Doctor 256 (58) 
     Nurse 40 (9) 
     Pharmacist  60 (14)  
     Community health worker 82 (19) 
If you already had tuberculosis, who would you go see first for your medications?  
     Doctor 360 (82) 
     Nurse 28 (7) 
     Pharmacist 19 (4) 
     Community health worker 31 (7) 
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Note: Multiple responses were permitted for this question; therefore, the percentages cannot be added together.   
The results basically represent rankings of the potential barriers. 
 
 
 
 
 
 
 
 
 
Table 4. Survey respondent opinions about potential barriers for asking questions to community pharmacists 
(n=438) 
Item No. (%) 
Fear or intimidation of asking the pharmacist 132 (30) 
Lack of awareness of the ability of the pharmacist to answer drug and disease related 
questions 
168 (38) 
Lack of the pharmacist’s knowledge to answer drug and disease related questions 112 (26) 
Busyness of the pharmacists 228 (52) 
Lack of privacy in the pharmacy 232 (53) 
Unavailability of the pharmacists to answer my questions 132 (30) 
Doctors are trusted more than pharmacists 200 (46) 
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Table 5. Survey respondent opinions about choice of healthcare professionals (n=438) 
Item No. (%) 
For each of the following, who would you go to first?  
Talk to me when I am fearful, distressed, concerned, or sad mentally or emotionally.  
     Doctor 294 (67) 
     Pharmacist 40 (9) 
     Nurse 104 (24) 
Talk to me about how to take medications.  
     Doctor 239 (55) 
     Pharmacist 143 (33) 
     Nurse 56 (12) 
Talk to me about how to take medications.  
     Doctor 227 (52) 
     Pharmacist 131 (30) 
     Nurse 80 (18) 
Talk to me about my drug related questions.  
     Doctor 268 (61) 
     Pharmacist 106 (24) 
     Nurse 64 (15) 
Talk to me about products I can get over-the-counter, such as cough and cold medicine.  
     Doctor 183 (42) 
     Pharmacist 152 (35) 
     Nurse 103 (23) 
